Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase

Modern therapy for acute TTP has resulted in a dramatic improvement in outcomes, with the combination of plasma exchange, immunosuppression, and caplacizumab being associated with >90% survival rates following an acute episode. TTP is no longer associated with just the acute episode, but requires...

Descripción completa

Detalles Bibliográficos
Autores principales: Westwood, John Paul, Scully, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340390/
https://www.ncbi.nlm.nih.gov/pubmed/35923772
http://dx.doi.org/10.1177/20406207221112217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340390/
https://www.ncbi.nlm.nih.gov/pubmed/35923772
http://dx.doi.org/10.1177/20406207221112217

Ejemplares similares